Novartis Adds New Therapies As Shares Trade Below Analyst Value Targets [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Novartis has received European Commission approval for Rhapsido (remibrutinib), the first oral targeted therapy for chronic spontaneous urticaria. The company has also secured World Health Organization prequalification for Coartem Baby, an antimalarial developed for newborns and infants. These twin regulatory milestones arrive as Novartis (SWX:NOVN) trades around CHF114.08, with the share price up 5.1% year to date and 25.9% over the past year. Over three and five years, the stock has returned 46.3% and 84.3% respectively, which helps frame how the market has treated the company while it has been building its current treatment portfolio. For readers tracking longer term themes, Rhapsido adds an oral option in chronic spontaneous urticaria, while Coartem Baby targets a very young and often underserved patient group. Together, these products broaden the therapy mix across specialty care and global health. These are factors that investors may watch alongside the existing performan
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies [MSNBC.com]MSNBC.com
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies [CNBC]CNBC
- Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income ... [Yahoo! Finance]Yahoo! Finance
- Novartis Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers [Forbes]Forbes
NVS
Earnings
- 4/28/26 - Miss
NVS
Sec Filings
- 4/28/26 - Form 6-K
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- NVS's page on the SEC website